#United States #California #Pomerantz LLP #Aardvark Therapeutics #ARD-101

Pomerantz Law Firm Files Class Action Lawsuit Against Aardvark Therapeutics

On September 24, 2026, Pomerantz LLP announced the initiation of a class action lawsuit against Aardvark Therapeutics, Inc. and several of its executives. This legal action has been filed in the Southern District of California under case number 26-cv-04643, and it targets those who purchased Aardvark common stocks either during its initial public offering (IPO) in February 2025 or within the specified class period, which runs until May 14, 2026.

The lawsuit alleges that Aardvark did not provide accurate information regarding its products and business performance, violating the Securities Act of 1933 and the Securities Exchange Act of 1934. Investors who acquired shares under misleading pretenses are urged to act promptly, as they have until October 13, 2026, to seek lead plaintiff status in the case.

Background of Aardvark Therapeutics

Aardvark is a biopharmaceutical company focused on developing small-molecule therapies aimed at reducing hunger and treating metabolic disorders, particularly Prader-Willi Syndrome (PWS). The company's chief product candidate, ARD-101, is designed to target Bitter Taste Receptors (TAS2Rs), which play a role in regulating hunger signaling in the brain. Aardvark's strategy involved pursuing a unique research direction by promoting its products as a breakthrough solution for hunger-related conditions.

Allegations of Misrepresentation

The complaint claims that Aardvark's IPO documentation was carelessly prepared. It contained misleading statements regarding the safety and effectiveness of ARD-101, and the commercial prospects associated with the product were overstated. In particular, the lawsuit accuses Aardvark's executives of failing to disclose critical safety concerns that arose during clinical studies.

The trouble began on February 27, 2026, when the company disclosed a voluntary halt in the Phase 3 HERO trial due to cardiac issues linked to ARD-101 at higher doses during safety routines. Following this announcement, Aardvark's stock plummeted by more than 56%, reflecting investor panic and loss of confidence in the company's direction.

In a subsequent announcement on May 14, 2026, Aardvark revealed that the U.S. Food and Drug Administration (FDA) had placed a clinical hold on its investigational new drug application for ARD-101. The regulatory intervention further contributed to a dramatic decrease in stock value, reinforcing claims of mismanagement.

Investor Implications

As the lawsuit unfolds, Pomerantz LLP reinforces its commitment to advocate for investors harmed by breaches of fiduciary duty and securities fraud. Established over 85 years ago, the firm has a solid reputation in securities class action litigation and has secured billions in damages for aggrieved stakeholders.

Investors who believe they have been compromised due to Aardvark’s alleged misconduct should seek legal counsel to discuss potential claims. Pomerantz LLP encourages interested parties to gather relevant documentation and reach out for guidance before the class action deadline passes.

As of the filing of this complaint, Aardvark’s stock was still trading below its initial offering price of $16 per share, a clear divergence from earlier optimistic projections made by its executives, indicating the impact of the ongoing legal battle on investor trust and market stability.